thalidomide has been researched along with Graves Ophthalmopathy in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Graves Ophthalmopathy: An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Zhang, X | 1 |
| Ma, L | 1 |
| Peng, F | 1 |
| Huang, J | 1 |
| Han, H | 1 |
| Tanda, ML | 1 |
| Piantanida, E | 1 |
| Bartalena, L | 1 |
2 other studies available for thalidomide and Graves Ophthalmopathy
| Article | Year |
|---|---|
Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.
Topics: 3T3-L1 Cells; Adipocytes, White; Adipogenesis; Animals; Cells, Cultured; Down-Regulation; Fatty Acid | 2012 |
Treating Graves' orbitopathy: where are we?
Topics: Adipocytes, White; Adipogenesis; Animals; Antithyroid Agents; Down-Regulation; Female; Graves Ophtha | 2012 |